Who is sponsoring NCT06574529?

NCT06574529 is sponsored by Ligue Pulmonaire Genevoise.

What drugs are being tested in NCT06574529?

Interventions in NCT06574529: Video-observed therapy (vDOT).

What condition does NCT06574529 study?

NCT06574529 studies Tuberculosis Active.

Is NCT06574529 still recruiting?

NCT06574529 is currently completed. Last updated 8 September 2025.

Last reviewed 2025-09-08 · How we verify

NCT06574529

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Video-observed Therapy for Active Tuberculosis: a Feasibility Study

Completed NA Last updated 8 September 2025

What this trial tests

NA trial testing Video-observed therapy (vDOT) in Tuberculosis Active in 51 participants. Completed in 31 May 2024.

Timeline

26 November 2021

Primary endpoint
18 July 2023

31 May 2024

Quick facts

Lead sponsor	Ligue Pulmonaire Genevoise
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	51
Start date	26 November 2021
Primary completion	18 July 2023
Estimated completion	31 May 2024
Sites	1 location across Switzerland

Drugs / interventions tested

Video-observed therapy (vDOT)

Conditions studied

Tuberculosis Active — all drugs for Tuberculosis Active →

Sponsor

Ligue Pulmonaire Genevoise

Who can join

16 and older, any sex, with Tuberculosis Active. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Tuberculosis (TB) is still present in Switzerland, and concerns mainly foreign-born subjects. Monitoring compliance to treatment by Directly Observed Therapy (DOT) is strongly encouraged by the World Health Organization (WHO). It is however time-consuming, costly and stigmatising. This study aims to examine the feasibility of monitoring compliance through a secured web platform and videos sent via an application on a cellphone, a concept known as vDOT (Video-observed therapy). The study aims to include all patients treated for tuberculosis is on our area during an 18 month period and monitor acceptance, compliance, and technical issues related to vDOT.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Tuberculosis Active

Currently open trials in the same condition.

NCT05840809 — Pharmacokinetics of Drugs Used to Treat Drug Sensitive Tuberculosis in Breastfeeding Mother-infant Pairs · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06574529 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ligue Pulmonaire Genevoise
Last refreshed: 8 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06574529.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing